US FDA staff raise efficacy concerns on Replimune's skin cancer drug ahead of meeting
28/07/2026 12:45
US FDA staff raise efficacy concerns on Replimune's skin cancer drug ahead of meeting July 28 (Reuters) - The U.S. FDA staff reviewers raised concerns on the efficacy of Replimune's REPL.O drug for a type of a skin cancer, ahead of their meeting on July 30, briefing documents showed on Tuesday.
Shares of the company were down 19.7% in premarket trading
(Reporting by Puyaan Singh in Bengaluru; Editing by Anil D'Silva)
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly